Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo?

Size: px
Start display at page:

Download "Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo?"

Transcription

1 Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Prof. Massimo Salvetti Clinica Medica University of Brescia

2 Percieved risk

3 Actual risk

4 Sehestedt et al, European Heart Journal 2010 Risk prediction is improved by adding markers of sublinical organ damage to SCORE

5 Stratification of total CV risk Further emphasis has been given to identification of organ damage, since hypertension-related asymptomatic alterations in several organs indicate progression in the CVD continuum, which markedly increases the risk beyond that caused by the simple presence of risk factors 2013 ESH/ESC Guidelines for the management of arterial hypertension

6 Evaluation of the elderly patient with known or suspected hypertension must accurately determine BP, and if elevated: 1) identify reversible and/or treatable causes; 2) evaluate for organ damage; 3) assess for other CVD risk factors/comorbid conditions affecting prognosis; and 4) identify barriers to treatment adherence. JACC 2014

7 Journal of Hypertension 2010 * p< Low * Moderate * * High * Routine + echocardiography + renal TOD + PWV + carotid ultrasound

8 Factors - other than office BP - influencing prognosis used for stratification of total CV risk (2) 2013 ESH/ESC Guidelines for the management of arterial hypertension

9 Search for asymptomatic organ damage - Kidney 2013 ESH/ESC Guidelines for the management of arterial hypertension

10 (incidence rate ratio) Hunt II Study, Arch Intern Med participants of the second Nord-Trøndelag Health Study (HUNT II), a Norwegian community-based health study, followed for 8.3 years with a 71% participation rate Cardiovascular mortality risk

11 The combined variable improved cardiovascular risk stratification at all age levels, but particularly in elderly persons where the predictive power of traditional risk factors is attenuated... Arch Intern Med. 2007

12 European Heart Journal 2007 Prospective study of 70-year-old men free from HF at baseline (Uppsala Longitudinal Study of Adult Men coho Cutoff: UAER median value, 4.7 mg/min In Cox proportional hazards models adjusted for established and novel risk factors for HF, a 1 SD increase in log UAER increased the risk of HF in individuals without anti hypertensive treatment (hazard ratio 1.49; 95% CI ; p < 0.005)

13 Search for asymptomatic organ damage - Arteries 2013 ESH/ESC Guidelines for the management of arterial hypertension

14 A man is as old as his arteries Thomas Sydenham,

15 Mannheim Carotid Intima-Media Thickness Consensus Update ( ) Cerebrovascular Disease 2007; ;23:75 80 plaque and IMT measurement according to Mannheim consensus. 1: thickness > 1.5 mm 2: lumen encroaching > 0.5 mm; 3, 4: > 50% of the surrounding IMT value

16 Unadjusted Cumulative Event-free Rates for the Combined End Point of Myocardial Infarction or Stroke, According to Quintile of Combined Intima-Media Thickness 5858 subjects 65 years of age or older, follow-up period of 6.2 years NEJM 1999, D.H. O Leary et al.

17 1289 men aged 60 to 74 years without a previous stroke or CHD Incidence of stroke Men with a plaque in the ICA had a 3-fold higher risk of stroke than those without The combination a plaque, of CCA and internal the carotid plaque artery (ICA) surface wall thickness irregularity was a further better predictor of the risk of stroke than was CCA wall thickness alone. increased the stroke risk. A significant excess risk of stroke was confined to men with an uncalcified plaque. Stroke 2004

18 DBP (mm Hg) DBP (mm Hg) SBP (mm Hg) SBP (mm Hg) DBP (mm Hg) DBP (mm Hg) SBP (mm Hg) SBP (mm Hg) Mean Systolic and Diastolic BP by Age and Race/Ethnicity for Men and Women (US Population ³Age 18 Years, NHANES III) Non-Hispanic Black Non-Hispanic White Mexican American Pulse pressure 110 Pulse pressure Men, Age (y) Women, Age (y) Burt VI, et al. Hypertension. 1995;25:

19 Compliance function of large arteries Arterial compliance Arterial compliance Left Ventricl e Peripheral resistances Left Ventricl e Peripheral resistances SYSTOLE DIASTOLE

20 Compliance function of large arteries Arterial compliance Arterial compliance Left Ventricl e Peripheral resistances Left Ventricl e Peripheral resistances SYSTOLE DIASTOLE

21 Carotid-femoral pulse wave velocity DL dp PWV. Dt. V dv Dt L Carotid femoral PWV can be assimilated to aortic stiffness

22 Reference values for pulse wave velocity (PWV): mean values according to age and blood pressure categories ( subjects) Reference Values for Arterial Stiffness' Collaboration. Eur Heart J 2010;31:

23 A cohort of 141 subjects (mean age, 87.1±6.6 years), dementia in 63.8 %, was studied in 3 geriatrics departments in a Paris suburb. During the 30-month follow-up, 56 patients died (27 from CV events). Logistic regressions indicated that age (p=0.005) and a loss of autonomy (p=0.01) were the best predictors of overall mortality. For cardiovascular mortality, aortic PWV was the major risk predictor (P0.016). Arterioscler Thromb Vasc Biol. 2001

24 Reclassification indices showed that the addition of apwv improved risk prediction (13% for 10-year CVD risk for intermediate risk). Ben Shlomo B et al, JACC 2014

25 Ben Shlomo et al, JACC 2014

26 280 eighty older subjects with subjective complaints of memory loss and no previous stroke (age 78.3±6.3 yrs) Interpretation: Systemic hemodynamic parameters (higher PWV and hypotension) together with cerebral microvascular damage (WML) are significantly associated with poorer cognitive function and may identify older subjects with subjective complaints of memory loss at higher risk of cognitive decline. International Journal of Cardiology 2013

27 Hypertension 2013; 61:

28 Hypertension 2014

29 Correlation between PWV and LV structure Studio Vobarno, Clinica Medica, Università di Brescia

30

31 Search for asymptomatic organ damage - Heart 2013 ESH/ESC Guidelines for the management of arterial hypertension

32 Increase in wall thickness with age in healthy men and women Bronx Longitudinal Study Aging Prevalence of concentric LV geometry increases with agenormalized RWT Values age-normalized RWTm = 0.41 RWTp = 0.40 Gerstenblith G et al. Circulation. 1977;56: de Simone G et al Hypertension. 2005;45:64-68

33 Prevalenza Disfunzione Diastolica (Criteri Primari) 60 % 50 p < p = p = p = p < Tutti M F C NC No Sì Controllo PA Sindrome Metabolica > > > 80 < Età PAS Zanchetti et al., J Hypertens 2007; 25:

34 LVH and CV Risk in Different Populations LVH diagnosed by echocardiography is a powerful predictor of myocardial infarction, stroke and CV death in: Apparently uncomplicated hypertensive patients In subjects with or without angiographic coronary heart disease In patients with previous myocardial infarction In subjects from general populations in epidemiological studies It has been estimated that 1g/m2 increase in LVMI is associated with a 1-2 % increase in the risk of CV events

35 Myocytes Cardiomyocite changes Hypertrophy Cell loss (apoptosis) Functional changes Systolic Dysfunction Pressure Overload Extracellular matrix Collagen network changes Reactive fibrosis Replacement fibrosis HF 26/01/ :09:55 Vascular Compartment Coronary disease Microcirculation changes Capillary rarefaction Diastolic Dysfunction

36 LV mass and incident heart failure The Cardiovascular Health Study Quartiles of echocardiographic LVM/BSA (g/m2): < 67.7, 67.8 to 79.2, 79.3 to 93.5, and > Drazner et al. JACC 2004; 43 :

37 In multivariable logistic regression models, including age, sex, BP levels, and use of antihypertensive drugs as covariates, the highest LVMI was found to be independently associated with a two-fold higher likelihood of having dementia. The association persisted significant even after adjustment for arterial stiffness

38 Sensitivity to detect treatment-induced changes, time to change and prognostic value of change by markers of asymptomatic OD 2013 ESH/ESC Guidelines for the management of arterial hypertension

39 VOBARNO Study 478 subjects (age range years) 40% elderly (193 subjects) % Prevalence of hypertension 53 Non elderly Χ 2 < Elderly Clinica Medica, University of Brescia % % Uncontrolled hypertension Χ 2 < Non elderly Elderly Resistant hypertension Χ 2 < Non elderly Elderly

40 Prevalence of OD 35 Prevalence of LVH % , ,1 Non elderly Elderly Studio Vobarno, Clinica Medica, Università di Brescia

41 Prevalence of OD Prevalence of IMT or plaques Prevalence of PWV>10 m/s % ,2 Non elderly 95,9 Elderly % ,1 Non elderly 68,5 Elderly Studio Vobarno, Clinica Medica, Università di Brescia

42 Grazie per l attenzione

43

44 8.4: Continued search for asymptomatic organ damage On the whole, it appears reasonable to search for at least some asymptomatic OD, not only for the initial stratification of CV risk, but also during follow-up 2013 ESH/ESC Guidelines for the management of arterial hypertension

45 0 BB VS OTHER DRUGS 31 paired comparisons 2680 pts 0 ARB VS OTHER DRUGS 20 paired comparisons 2384 pts BB -8,8 Other drugs * -11, * -12,6-9,4 ARB Other drugs * p<0.01 Pairwise Comparison of Each Drug Class With the Other Classes Statistically Combined Fagard et al, Hypertension 2009

46 Treatment Age Years Treatment Duration N pts Change in LVM % Change in SBP mmhg Terpstra W et al 2000 ELVERA Lisinopril years % -26 Amlodipine % Schulman S et al 1990 Verapamil > 60 years 6 months % -28 atenolol % -32 Dahlof et al 2004 LIFE Losartan years 6 months % -30 Mean age Atenolol % yrs

47 Comparative effect of antihypertensive drugs on aortic stiffness, wave reflection and central PP Aortic PWV Central PP, Augmentation index ACE-Inhibitors Angiotensin Receptor Blockers Calcium channel blockers Thiazide diuretics Vasodilating β-blockers Non vasodilating β-blockers

48 22 trials published between 1996 and 2005: - 8 trials antihypertensive drugs vs placebo or no-treatment - 9 trials new with old drug classes - 5 trials ACE inhibitors and CCBs Conclusions: Calcium channel blockers reduce carotid intima-media thickening. This mechanism might contribute to their superior protection against stroke. Stroke online June 8, 2006

49

When should you treat blood pressure in the young?

When should you treat blood pressure in the young? ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department

More information

Central Pressures and Prehypertension

Central Pressures and Prehypertension Central Pressures and Prehypertension Charalambos Vlachopoulos Associate Professor of Cardiology 1 st Cardiology Dept Athens Medical School Central Pressures and Prehypertension Charalambos Vlachopoulos

More information

How clinically important are the results of the large trials in hypertension?

How clinically important are the results of the large trials in hypertension? How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université

More information

Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις

Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις Ελένη Τριανταφυλλίδη Επιμελήτρια Α Β Πανεπιστημιακή Καρδιολογική Κλινική Αττικό Νοσοκομείο

More information

HTA ET DIALYSE DR ALAIN GUERIN

HTA ET DIALYSE DR ALAIN GUERIN HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age

More information

Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski

Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly Piotr Jankowski I Department of Cardiology and Hypertension CM UJ, Kraków, Poland piotrjankowski@interia.pl Vienna,

More information

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University

More information

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,

More information

Early Detection of Damaged Organ

Early Detection of Damaged Organ Early Detection of Damaged Organ Regional Cardiovascular Center, Chungbuk National University Kyung-Kuk Hwang Contents NICE guideline 2011 - Confirm the diagnosis of HT ambulatory blood pressure monitoring

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

Managing HTN in the Elderly: How Low to Go

Managing HTN in the Elderly: How Low to Go Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular

More information

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Egyptian Hypertension Guidelines

Egyptian Hypertension Guidelines Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich

More information

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

Slide notes: References:

Slide notes: References: 1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory

More information

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic 1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker

More information

Effects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France

Effects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France Effects of Renin-Angiotensin System blockade on arterial stiffness and function Gérard M. LONDON Manhès Hospital Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance

More information

Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016

Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016 The differential effect of Atherosclerosis on end organ damage in adult and elderly patients with CVRF: New Algorithm for Hypertension Diagnosis and Treatment R. Zimlichman, FAHA, FASH, FESC, FESH Chief

More information

Background. Metabolic syndrome T2DM CARDIOVASCULAR DISEASE. Major Unmet Clinical Need. Novel Risk Factors. Classical Risk Factors LDL-C.

Background. Metabolic syndrome T2DM CARDIOVASCULAR DISEASE. Major Unmet Clinical Need. Novel Risk Factors. Classical Risk Factors LDL-C. The effect of metabolic syndrome for left ventricular geometry, arterial stiffness and carotid intima-media thickness in Korean general population Result from Atherosclerosis RIsk of Rural Area in Korea

More information

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated

More information

Arterial Pressure in CKD5 - ESRD Population Gérard M. London

Arterial Pressure in CKD5 - ESRD Population Gérard M. London Arterial Pressure in CKD5 - ESRD Population Gérard M. London INSERM U970 Paris 150 SBP & DBP by Age, Ethnicity &Gender (US Population Age 18 Years, NHANES III) 150 SBP (mm Hg) 130 110 80 Non-Hispanic Black

More information

Update in Hypertension

Update in Hypertension Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded

More information

Cardiovascular Diseases in CKD

Cardiovascular Diseases in CKD 1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9

More information

THE HEART AND HYPERTENSION. Philippe Gosse Hypertension Unit University Hospital Bordeaux

THE HEART AND HYPERTENSION. Philippe Gosse Hypertension Unit University Hospital Bordeaux THE HEART AND HYPERTENSION Philippe Gosse Hypertension Unit University Hospital Bordeaux INCREASED LVM Cardiomyocytes hypertrophy is a response to pressure overload This response is influenced by many

More information

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial 1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.

More information

The monthly ESH guide through publications

The monthly ESH guide through publications NEWSLETTER APRIL 2016 The monthly ESH guide through publications Edited by: Prof Costas Tsioufis, ESH Secretary and Dr Alex Kasiakogias Effects of hypertension treatment on heart failure: insights from

More information

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria 1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage

More information

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals

More information

Arterial function and longevity Focus on the aorta

Arterial function and longevity Focus on the aorta Arterial function and longevity Focus on the aorta Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Secrets of longevity Secrets of longevity Unveiling

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time. Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France

Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time. Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France The causes of Cardiovascular Diseases in CKD Systolic BP;

More information

Endothelial function is impaired in women who had pre-eclampsia

Endothelial function is impaired in women who had pre-eclampsia Endothelial function is impaired in women who had pre-eclampsia Christian Delles, Catriona E Brown, Joanne Flynn, David M Carty Institute of Cardiovascular and Medical Sciences University of Glasgow United

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

Blood Pressure Targets in Diabetes

Blood Pressure Targets in Diabetes Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

INTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING

INTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING INTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING VASOTENS Registry Vascular health ASsessment Of The hypertensive patients Project Coordinator: Dr. Stefano Omboni

More information

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension. 2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk

More information

47 Hypertension in Elderly

47 Hypertension in Elderly 47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary

More information

Hypertension in Aortic Valve Disease

Hypertension in Aortic Valve Disease Hypertension in Aortic Valve Disease Hanna M. Nosseir MRCP, FRCP Head of Cardiology department Galaa Military Medical Complex Aortic stenosis: Introduction Arterial hypertension and aortic stenosis are

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%

More information

An Epidemiological Overview

An Epidemiological Overview An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in

More information

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Pharmacotherapy: A Practical Approach Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.

More information

Preventing Early Vascular Ageing (EVA) and its hemodynamic changes

Preventing Early Vascular Ageing (EVA) and its hemodynamic changes Translational Research 31 st October 2013, Moscow Preventing Early Vascular Ageing (EVA) and its hemodynamic changes Peter M Nilsson, MD, PhD Department of Clinical Sciences Lund University University

More information

Incidental Findings; Management of patients presenting with high BP. Phil Swales

Incidental Findings; Management of patients presenting with high BP. Phil Swales Incidental Findings; Management of patients presenting with high BP Phil Swales Consultant Physician Acute & General Medicine University Hospitals of Leicester NHS Trust Objectives The approach to an incidental

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart

More information

D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis

D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis,

More information

Clinical application of Arterial stiffness. pulse wave analysis pulse wave velocity

Clinical application of Arterial stiffness. pulse wave analysis pulse wave velocity Clinical application of Arterial stiffness pulse wave analysis pulse wave velocity Arterial system 1. Large arteries: elastic arteries Aorta, carotid, iliac, Buffering reserve: store blood during systole

More information

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,

More information

STANDARD treatment algorithm mmHg

STANDARD treatment algorithm mmHg STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If

More information

Pharmacological modulation of vascular structure and function. L. Van Bortel. Heymans Institute of Pharmacology, Ghent University

Pharmacological modulation of vascular structure and function. L. Van Bortel. Heymans Institute of Pharmacology, Ghent University Pharmacological modulation of vascular structure and function L. Van Bortel Heymans Institute of Pharmacology, Ghent University BHC 2015 Pharmacological modulation of Endothelial function CIMT Pulse wave

More information

Combination Therapy for Hypertension

Combination Therapy for Hypertension Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

Treating Hypertension in 2018: What Makes the Most Sense Today?

Treating Hypertension in 2018: What Makes the Most Sense Today? Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or

More information

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step

More information

Preventing and Treating High Blood Pressure

Preventing and Treating High Blood Pressure Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure

More information

Individual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki

Individual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki Individual management of arterial hypertension Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki From Population to Individual Management of Arterial Hypertension Epidemiologic impact

More information

Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease

Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Michelle P Kao, Donald S Ang, Steve Gandy, Chim C Lang, Allan D Struthers Division of

More information

Causes of Poor BP control Rates

Causes of Poor BP control Rates Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular

More information

Which method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호

Which method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호 Which method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호 Arterial stiffness Arterial stiffness is inversely related to arterial

More information

Coronary artery disease (CAD) risk factors

Coronary artery disease (CAD) risk factors Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

An Epidemiological Overview

An Epidemiological Overview An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in

More information

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef Review of Cardiac Imaging Modalities in the Renal Patient George Youssef ECHO Left ventricular hypertrophy (LVH) assessment Diastolic dysfunction Stress ECHO Cardiac CT angiography Echocardiography - positives

More information

Update on Current Trends in Hypertension Management

Update on Current Trends in Hypertension Management Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B) Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed

More information

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular

More information

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016 Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34

More information

Falls Assessment and Medication

Falls Assessment and Medication Falls Assessment and Medication Professor T.Masud President-Elect British Geriatrics Society Nottingham University Hospitals NHS Trust, UK Visiting Professor University of Southern Denmark Mrs GH is a

More information

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with

More information

Hypertension and Cardiovascular Disease

Hypertension and Cardiovascular Disease Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,

More information

Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia?

Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia? 2012. 4. 20-21 춘계심장학회 _ 부산 Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia? Jeong Bae Park, MD, PhD Cardiology, Cheil General Hospital, Kwandong University, Seoul, Korea The Pulse : revived

More information

Modern Management of Hypertension

Modern Management of Hypertension Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT

More information

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs

More information

Abstract nr AHA, Chicago November European Heart Journal Cardiovascular Imaging, in press. Nr Peter Blomstrand

Abstract nr AHA, Chicago November European Heart Journal Cardiovascular Imaging, in press. Nr Peter Blomstrand Left Ventricular Diastolic Function Assessed by Echocardiography and Tissue Doppler Imaging is a strong Predictor of Cardiovascular Events in Patients with Diabetes Mellitus Type 2 Peter Blomstrand, Martin

More information

Hypertension Management Focus on new RAAS blocker. Disclosure

Hypertension Management Focus on new RAAS blocker. Disclosure Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

Improving risk prediction focusing on intermediate endpoints. Arterial stiffness. Pr. Stéphane LAURENT, MD, PhD, FESC

Improving risk prediction focusing on intermediate endpoints. Arterial stiffness. Pr. Stéphane LAURENT, MD, PhD, FESC Improving risk prediction focusing on intermediate endpoints Arterial stiffness Pr. Stéphane LAURENT, MD, PhD, FESC Pharmacology Department, Hôpital Européen Georges Pompidou, Paris Cardiovascular Research

More information

Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D.

Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D. Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D. TensioMed Arterial Stiffness Centre, Budapest Heart Institute, Faculty of Medicine, University of Pécs

More information

Estimated Pulse Wave Velocity Calculated from Age and Mean Arterial Blood Pressure

Estimated Pulse Wave Velocity Calculated from Age and Mean Arterial Blood Pressure Received: August 19, 2016 Accepted after revision: November 4, 2016 Published online: December 1, 2016 2235 8676/16/0044 0175$39.50/0 Mini-Review Estimated Pulse Wave Velocity Calculated from Age and Mean

More information

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult

More information

How do we diagnose hypertension today? Presentation Subtitle

How do we diagnose hypertension today? Presentation Subtitle How do we diagnose hypertension today? Presentation Subtitle Renata Cífková Case 1 JM, a 64-year-old lady referred to our center because of undesirable effects of her antihypertensive medication Personal

More information

Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?

Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,

More information

Which CVS risk reduction strategy fits better to carotid US findings?

Which CVS risk reduction strategy fits better to carotid US findings? Which CVS risk reduction strategy fits better to carotid US findings? Dougalis A, Soulaidopoulos S, Cholongitas E, Chalevas P, Vettas Ch, Doumtsis P, Vaitsi K, Diavasti M, Mandala E, Garyfallos A 4th Department

More information

Dr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra

Dr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra Dr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra Beta-blockers were used in several longterm morbidity and trials in the treatment of hypertension, either alone or in comparison

More information

Prevention of Heart Failure: What s New with Hypertension

Prevention of Heart Failure: What s New with Hypertension Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults

More information